Search

Displaying results 4971 - 4980 of 8010 in total
  1. Drug

    Oglufanide

    go.drugbank.com/drugs/DB05779
    Investigational

    Oglufanide is a synthetic dipeptide immunomodulator in development for the treatment of chronic hepatitis C viral infection. … Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Tertomotide

    go.drugbank.com/drugs/DB12747
    Investigational

    It is being developed by Pharmexa A/S. … Tertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma).

  3. Drug

    5,7,2′-trihydroxy-6,8-dimethoxyflavone

    go.drugbank.com/drugs/DB13983
    Experimental

    5,7,2′-trihydroxy-6,8-dimethoxyflavone (K36) is a high-affinity, naturally occurring flavonoid derivative isolated from the medicinal herb _Scutellaria baicalensis_ Georgi [A31656].

  4. Drug

    TPIV 200

    go.drugbank.com/drugs/DB17318
    Investigational

    TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).

  5. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  6. Drug

    Benactyzine

    go.drugbank.com/drugs/DB09023
    ApprovedWithdrawn

    Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.

  7. Drug

    Sultamicillin

    go.drugbank.com/drugs/DB12127
    ApprovedWithdrawn

    Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: SULTAMICILINA MK 250 MG/5ML
  8. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation … R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated

  9. Target

    Immunoglobulin heavy variable 3-30

    go.drugbank.com/bio_entities/BE0004312
    TargetHumans

    Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. … variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for

    Synonyms: Ig heavy chain V-III region BUR
  10. Drug

    Orbifloxacin

    go.drugbank.com/drugs/DB11443
    ExperimentalVet approved

    It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.